Treatment with BY40, a CD39 blocking antibody currently under preclinical development, reduces the inhibition of CD4+ and CD8+T cell proliferation, which is induced by tumor tissue and increases cytotoxicity mediated by cytotoxic T lymphocytes (CTL) and NK cells (16). The gene discussed is CD8A; the disease is neoplasm.